Search results
Results from the WOW.Com Content Network
As with previous GINA reports, the 2024 report is based on a twice annual update of the evidence, which forms the basis for the recommendations made by the GINA Science Committee. The committee, which is comprised of leaders in adult and pediatric asthma research, performed a full-text review for 64 publications, of which 34 publications were ...
Shifts in Thinking About COPD. Although many changes in the 2024 report reflect new research released from January 2022 to July 2023 (148 new references in total), the updated report does more than just incorporate this new research, said Dr Vogelmeier. The new “consolidated” report continues to refine the definition of COPD and pre-COPD ...
January 5, 2024. Patients with COPD are at a much higher risk for health complications secondary to infection. The value of vaccination in COPD is clear and has been so for decades. Now, guidelines in the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) 2024 Report have also been updated to align with Centers for Disease ...
The 2023 report from the Global Initiative for Chronic Obstructive Lung Disease (GOLD) — “Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease” (COPD) 1 — details “an expanded range of therapies for COPD that now can be considered to improve mortality,” according to Gerard J. Criner, MD, FACP, FACCP, an author of the 2023 GOLD ...
Colby Stong. |. May 13, 2024. STAR stage 1 (using FEV1/FVC) proved more robust than GOLD stage 1 (using FEV1pp) in identifying breathlessness and mortality risk in those without airflow obstruction. Two measures for assessing airflow obstruction — the ratio of forced expiratory volume in the first second to forced vital capacity (FEV 1 /FVC ...
COVID-19 vaccines for 2024–2025 are recommended in all individuals aged 6 months and older in the United States, with vaccines approved and authorized in August that include those by Moderna and Pfizer-BioNtech (targeting the KP.2 strain) and the Novavax, (targeting the JN.1 strain).
October 1, 2024. Treatment with dupilumab reduced the annualized rate of moderate or severe COPD exacerbations by 30% in the BOREAS trial and 34% in the NOTUS trial compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance therapy for adults with inadequately controlled chronic ...
December 16, 2019. Based on emerging new evidence, a multidisciplinary panel of experts put together by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) released updated recommendations for the management of adults with community-acquired pneumonia (CAP). This report was published in Annals of the American ...
2024 GOLD Guidelines Stress the Importance of Vaccines for Patients With COPD By Naveed Saleh, MD, MS Patients with stable COPD should receive vaccinations for influenza, pneumococcal pneumonia, herpes zoster, RSV, and COVID-19, according to 2024 GOLD COPD guidelines.
ChatGPT treatment recommendations for atopic dermatitis (AD) often differ the recommendations based on established clinical guidelines, according to study results presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting, held October 24 to 28 in Boston, Massachusetts.